Veterinary Medicines

Aftovaxpur DOE (60) O1 BFS + SAT2 Saudi Arabia

Authorised
  • Foot-and-mouth disease virus, serotype O, strain O1 BFS, Inactivated
  • Foot-and-mouth disease virus, serotype SAT2, strain Saudi Arabia, Inactivated
Download as PDF

Product identification

Medicine name:
Aftovaxpur DOE (60) O1 BFS + SAT2 Saudi Arabia
Active substance:
  • Foot-and-mouth disease virus, serotype O, strain O1 BFS, Inactivated
  • Foot-and-mouth disease virus, serotype SAT2, strain Saudi Arabia, Inactivated
Target species:
  • Cattle
  • Sheep
  • Pig
Route of administration:
  • Intramuscular use
  • Subcutaneous use

Product details

Active substance and strength:
  • Foot-and-mouth disease virus, serotype O, strain O1 BFS, Inactivated
    Presentation_strength:? 6 PD50 Reference:Hse Index:0
  • Foot-and-mouth disease virus, serotype SAT2, strain Saudi Arabia, Inactivated
    Presentation_strength:? 6 PD50 Index:11
Pharmaceutical form:
  • Emulsion for injection
Withdrawal period by route of administration:
  • Intramuscular use
    • Cattle
      • Not applicable
        0
        day
    • Sheep
      • Not applicable
        0
        day
    • Pig
      • Not applicable
        0
        day
  • Subcutaneous use
    • Cattle
      • Not applicable
        0
        day
    • Sheep
      • Not applicable
        0
        day
    • Pig
      • Not applicable
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI02AA04
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Iceland
  • Ireland
  • Italy
  • Latvia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Malta
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Boehringer Ingelheim Vetmedica GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
  • Boehringer Ingelheim Animal Health France
Responsible authority:
  • European Commission
Authorisation number:
This information is not available for this product.
Date of authorisation status change:

Documents

Combined File of all Documents

English (PDF)
Published on: 19/03/2024
Download
Bulgarian (PDF)
Published on: 19/03/2024
Download
Croatian (PDF)
Published on: 19/03/2024
Download
Czech (PDF)
Published on: 19/03/2024
Download
Danish (PDF)
Published on: 19/03/2024
Download
Dutch (PDF)
Published on: 19/03/2024
Download
Estonian (PDF)
Published on: 19/03/2024
Download
Finnish (PDF)
Published on: 19/03/2024
Download
French (PDF)
Published on: 19/03/2024
Download
German (PDF)
Published on: 19/03/2024
Download
Greek (PDF)
Published on: 19/03/2024
Download
Hungarian (PDF)
Published on: 19/03/2024
Download
Icelandic (PDF)
Published on: 19/03/2024
Download
Italian (PDF)
Published on: 19/03/2024
Download
Latvian (PDF)
Published on: 19/03/2024
Download
Lithuanian (PDF)
Published on: 19/03/2024
Download
Maltese (PDF)
Published on: 19/03/2024
Download
Norwegian (PDF)
Published on: 19/03/2024
Download
Polish (PDF)
Published on: 19/03/2024
Download
Portuguese (PDF)
Published on: 19/03/2024
Download
Romanian (PDF)
Published on: 19/03/2024
Download
Slovak (PDF)
Published on: 19/03/2024
Download
Slovenian (PDF)
Published on: 19/03/2024
Download
Spanish (PDF)
Published on: 19/03/2024
Download
Swedish (PDF)
Published on: 19/03/2024
Download

ema-puar-aftovaxpur-v-2292-var-ii-0001-en.pdf

English (PDF)
Published on: 6/02/2023
Download

ema-puar-aftovaxpur-v-2292-par-en.pdf

English (PDF)
Published on: 6/02/2023
Download

ema-puar-aftovaxpur-v-2292-var-ii-0009-en.pdf

English (PDF)
Published on: 6/02/2023
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."